Get started

Pharmaceuticals

ACAD (ACADIA PHARMACEUTICALS INC) BUY ACAD LONG SET UP, ACAD Gapped down over 25% to a New 52 week low. Price should bounce and fill in the Gap in the market ACAD also filled its previous Buy gap from Sep 4th 2019 Title: Buy ACAD (ACADIA Pharmaceuticals) Asset: Stock Platform: Robinhood/WeBull/Etrade/ 401k account Symbol: ACAD Type: Buy Market Execution / Buy Limit Time Frame: 1D Entry Price 1: $26.50 ACTIVE Entry Price 2: $22.50(PENDING) Stop Loss: $19.50 (70 Pips) Take Profit 1: $33.00 (70 pips) Take Profit 2: $38.00 (140 pips) Take Profit 3: $44.00 (200 pips) Take Profit 4: $54.00 (300pips) Status: 🏃🏽‍♂️Active🏃🏽‍♂️ Sector: Health Technology Industry: Biotechnology ACADIA Pharmaceuticals operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R Brann on July 16, 1993 and is headquartered in San Diego CA
NASDAQ:ACADLong
by MavRich_Trading
3
After six-week slide, I am buying MerckMerck is one of my favorite pharmaceutical companies. As far as I can tell, it a genuinely ethical and well-managed company with an above-average ESG rating. Merck has executed pretty consistently, with an average of 2% annual sales growth, 2.5% annual dividend growth, 3% annual earnings growth, and 4% annual free cash flow growth over the past several years. Merck's valuation is quite attractive for a growing, large-cap company. I estimate its forward P/E at 10, forward P/S at 3.4, and PEG under 5. Merck's dividend yield is a juicy 3.76%, and they should have no problem sustaining that given their free cash flow growth. I estimate that Merck has about 16% upside to its median price multiple of the last four years. Market sentiment is quite bullish on Merck. The average analyst summary score is a "buy" at 6.4/10. Merck has about 30% upside to its average analyst price target. Open interest from option traders is in highly bullish territory, with a put-call ratio of 0.56. News lately has been a bit negative for Merck. Today they voluntarily withdrew their drug Keytruda for one of its (many) indications because it didn't meet FDA post-marketing requirements. That's not great, but it won't be devastating to Keytruda revenues. Merck's proposed purchase of Pandion Therapeutics is being investigated for procedural problems, which also isn't great. Plus, the FDA delayed approval of Merck's application for emergency approval for its Covid-19 drug until it produces more data. On the other hand, Merck just submitted a New Drug Application for gefapixant and cut a billion-dollar commercialization deal for Xevinapant. Both those things are positives for the company. Plus, Merck got some positive attention recently due to a large purchase of its stock by Warren Buffett's investment fund. In technical terms, Merck obviously has been in a downtrend, but it's approaching trend line support. I'm looking at buy tomorrow in the $71.50-71.75 range if Merck continues to dip toward support.
NYSE:MRKLong
by ChristopherCarrollSmith
3
MRK - Merck & Co - WEEKLY Setup - Holding the 200emaI Hate Trading Pharma But... MRK BUYZONE = 74 - 76 Cost Avg Down (CAD) = 72 - 70 1st Target = 79 2nd Target = 82 3rd Target = 86 HODL Target = ATH ______________________________________________________________________________________________________________________ This content is for informational, educational and entertainment purposes only. This is not in any way, shape or form financial or trading advice. Good luck, happy trading and stay chill, 2degreez
NYSE:MRKLong
by UnknownUnicorn7216011
Let's make some SERIOUS money! (CGIX)Seeing a turn in cancer genetics incorporated... looks juicy. Triple bottom structure with a recent falling wedge breakout on the overall expanding downward channel. Each time on the turning point of this major multi year support we saw major impulsive moves shortly after. Given that the price in time now is at a much lower discount compared to history. I think that is why we are seeing the triple bottom of accumulation. This correction to these lows also has been a bigger move just in general based off history. This could be the beginning of a major bull cycle. I feel good sitting in this one here. Another plus is that this has a low float. Anything I trade will always have a low float. (Less Outstanding Shares) Remember I trade long term. I look for major multi year turning points in markets. The longer I can hold a trade, the better! I specifically analyze the weekly and the monthly, nothing else! Thanks for checking out my analysis, check out some of my extra work on my page.
CLong
by UnknownUnicorn2319099
9